First FDA Approved Tablets for ADHD Treatment
Shionogi Inc. has brought out KAPVAY tablets for treating children suffering from ADHD (Attention Deficit Hyperactivity Disorder). This oral tablet is an extended release of clonidine hydrochloride version of the same company. This tablet is also the first to be approved by the US Food and Drug Administration as a viable add-on therapy for children and adolescents suffering from ADHD.
The Chief Medical Officer of Shionogi Inc., Dr. Donald C. Manning has said that this extended version of clonidine offers a treatment option to all those kids and adolescents who do not respond to stimulants alone.
Four and a half million children in America suffer from ADHD and only 30 percent of these kids respond to stimulant mono-therapy. Children who suffer from this condition have a lack of control over their behaviour and attention in some situations and become hyperactive in various other situations.
The FDA has approved this drug only after looking at the results of two Phase III studies. In the week 5 of the clinical trial, the efficacy of KAPVAY was demonstrated with the help of a ADHD rating scale. Also, any adverse side-effects like fatigue and somnolence was only found to be either mild or moderate.